4/13/2021 7:02:23 AM
Rigel Reports Positive Topline Results From Phase 2 Clinical Trial To Evaluate Safety Of Fostamatinib
4/7/2021 7:31:13 AM
Rigel Announces Closing Of License Agreement With Lilly
3/11/2021 7:36:55 AM
Rigel Completes Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In COVID-19 Patients
3/2/2021 4:02:42 PM
Rigel Pharmaceuticals Q4 Loss/share $0.11 Vs. Loss $0.10 Year Ago
2/18/2021 6:34:55 AM
Lilly, Rigel Announce Global License Agreement To Co-develop Rigel's R552 In All Indications
1/29/2021 2:51:24 PM
Rigel Gets $16.5 Mln From U.S. Department Of Defense For Phase 3 Clinical Trial Of Fostamatinib In COVID-19 Patients
1/11/2021 7:34:10 AM
Rigel Pharma Reports 2020 TAVALISSE Preliminary Net Product Sales Of About $61.7 Mln
11/17/2020 7:37:21 AM
Rigel Pharma Reaches Agreement With FDA On Final Design Of FORWARD Study
11/5/2020 4:04:49 PM
Rigel Pharma Q3 Loss/share $0.08 Vs. Loss $0.07 Year Ago